Loading news...
5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CAO Edward Carr sold 43,682 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a document filed with the Securities and Exchange Commission,
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Simrat Randhawa sold 33,830 shares of the firm's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The transaction was disclosed in a legal filing with the Securities and Exchange Commission,
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a legal filing with the SEC, which
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it closed its previously announced underwritten public offering of 8,470,989 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 1,157,407 shares, at a public offering price of $81.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering were approximately $719 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Dianthus. All of the securities were offered by Dianthus.
NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock at a public offering price per share of $81.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately $625 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Dianthus, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,157,407 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Dianthus.
Dianthus Therapeutics, Inc. is maintained at a Buy rating, supported by strong clinical progress and a 174.53% stock gain since the last update. Claseprubart delivered statistically significant MG-ADL improvements in phase 2 Myasthenia Gravis and is advancing to phase 3, with topline data expected in 2H 2028. An early "GO decision" for the phase 3 CAPTIVATE trial in CIDP, driven by positive interim response rates, sets up a key DNTH catalyst with top-line data release update year-end 2026.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) shares hit a new 52-week high on Tuesday after HC Wainwright raised their price target on the stock from $47.00 to $130.00. HC Wainwright currently has a buy rating on the stock. Dianthus Therapeutics traded as high as $84.86 and last traded at $79.23, with a volume
Dianthus Therapeutics, Inc. (DNTH) Discusses Interim Responder Analysis and Early Go Decision for CAPTIVATE Trial in CIDP Transcript
NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Dianthus.
Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $0.81 per share a year ago.
CIDP is a rare, acquired autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, causing progressive or relapsing muscle weakness, numbness, and sensory loss lasting over 8 weeks.
Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: Company will maintain the Part A dose of 300mg/2mL S.C. Q2W, plans to engage with regulators to remove the 600mg/4mL S.C.
NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET.
Citigroup Inc. raised its position in Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 486.8% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 68,479 shares of the company's stock after purchasing an additional 56,809 shares during the period. Citigroup Inc. owned approximately 0.21% of
Dianthus Therapeutics, Inc. (DNTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NEW YORK and WALTHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on March 2, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the TD Cowen 46th Annual Health Care Conference in Boston.